Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is RAIN-32, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing RAIN-32 that has completed Phase II clinical trial in liposarcoma, Phase I clinical trial in solid tumors, and Phase II clinical trial in intimal sarcoma, as well as RAD52 for tumors, including breast, ovarian, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
IPO Year:
Exchange: NASDAQ
Website: rainthera.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
5/30/2023 | Buy → Neutral | ROTH MKM | |
3/21/2023 | $11.00 | Outperform | SVB Securities |
1/31/2023 | $21.00 | Buy | ROTH Capital |
1/23/2023 | $18.00 | Buy | Mizuho |
9/12/2022 | $10.00 | Buy | H.C. Wainwright |
4/1/2022 | $15.00 | Outperform | Oppenheimer |
9/14/2021 | $22.00 | Neutral | Goldman |
7/20/2021 | $25.00 | Overweight | Piper Sandler |